BiotechTube
Home/Pipeline/MIGRA-NP01

MIGRA-NP01

Pancreatic Cancer

PreclinicalActive

Key Facts

Indication
Pancreatic Cancer
Phase
Preclinical
Status
Active
Company
Migra-Therapeutics

About Migra-Therapeutics

MIGRA-Therapeutics is a private, preclinical-stage biotech focused on overcoming a major hurdle in cancer treatment: delivering therapeutics effectively into dense, resistant solid tumors. The company's platform utilizes hyaluronic acid nanoparticles and protease-enabled systems to create stroma-penetrating delivery vehicles for both chemotherapy drugs and therapeutic cells like CAR-Ts. With foundational support from NIH SBIR grants and strong academic ties, MIGRA is advancing its lead candidate, MIGRA-NP01, towards IND-enabling studies for pancreatic cancer while seeking partnerships to broaden the platform's application.

View full company profile

Therapeutic Areas

Oncology

Other Pancreatic Cancer Drugs

DrugCompanyPhase
Ampligen® (rintatolimod)AIM ImmunoTechEarly Access Program
HBM9027Harbour BioMedPhase 1
Small-Molecule TherapeuticAIkido LabsPre-clinical
AHPBA IRE RegistryAngioDynamicsPost-Market Registry
SIMBs + ImmunotherapyAdvanced MicrobubblesPre-clinical
CLS-014CLS TherapeuticsPre-clinical
SOMA PlatformCoherence NeuroPre-clinical
NP-G2-044Novita PharmaceuticalsPhase 2a
Pritumumab (PTB)Nascent BiotechPhase II (Planned)
Pancreatic Cancer TestMosaique DiagnosticDevelopment
Iontophoretic SystemContinuity BiosciencesPre-clinical
Lixumistat (IM156)ImmunoMet TherapeuticsPhase 1b